Tsumura & Co. (JP:4540)
:4540
4540 Stock Chart & Stats
¥3599.00
¥9.00(0.19%)
At close: 4:00 PM EST
¥3599.00
¥9.00(0.19%)
Day’s Range― - ―
52-Week Range¥3,306.00 - ¥4,480.00
Previous CloseN/A
Volume145.30K
Average Volume (3M)448.06K
Market Cap
¥294.10B
Enterprise Value¥351.90B
Total Cash (Recent Filing)¥69.48B
Total Debt (Recent Filing)¥135.41B
Price to Earnings (P/E)7.1
Beta0.53
Next Earnings
May 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.3%
Share Statistics
EPS (TTM)142.95
Shares Outstanding76,758,360
10 Day Avg. Volume373,220
30 Day Avg. Volume448,060
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)1.09
Price to Sales (P/S)1.81
P/FCF Ratio52.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)340.93
Revenue Forecast (FY)¥196.75B
Bulls Say, Bears Say
Bulls Say
Profitability & Revenue GrowthSustained gross and healthy net margins alongside multi-year revenue expansion indicate durable operational profitability and pricing power in core products. This supports reinvestment in manufacturing and R&D, and cushions earnings through industry cycles, underpinning long-term cash generation potential.
Substantial Equity BaseA large equity base provides a structural financial buffer, enabling the company to absorb volatility in raw-material supply and invest in production capacity. This strengthens credit standing and preserves strategic optionality for capex or M&A without immediate dependence on short-term market financing.
Reimbursed Prescription BusinessA reimbursed prescription model creates recurring demand, tight physician/distributor relationships, and regulatory barriers that limit new entrants. Reliance on Japan’s healthcare reimbursement offers structural revenue stability and predictable volume trends over multiple months to years.
Bears Say
Weak Cash GenerationNegative trailing free cash flow signals persistent cash conversion issues despite reported profits. This raises reliance on external financing for capex, working capital and dividends, constraining strategic flexibility and increasing execution risk if cash conversion doesn't recover sustainably.
Rising LeverageA sharp increase in debt relative to prior-year levels reduces financial headroom and raises interest and refinancing exposure. With weaker cash conversion, higher leverage heightens default and credit-cost risk and can force prioritization of debt service over growth investments or shareholder returns.
Margin & ROE SofteningDeclining margins and lower ROE indicate erosion in earnings quality and returns on capital. If driven by cost pressures or pricing constraints, these trends can persist and reduce the payoff from invested capital, making it harder to rebuild cash flow and justify sustained capital deployment.
Tsumura & Co News
4540 FAQ
What was Tsumura & Co.’s price range in the past 12 months?
Tsumura & Co. lowest stock price was ¥3306.00 and its highest was ¥4480.00 in the past 12 months.
What is Tsumura & Co.’s market cap?
Tsumura & Co.’s market cap is ¥294.10B.
When is Tsumura & Co.’s upcoming earnings report date?
Tsumura & Co.’s upcoming earnings report date is May 12, 2026 which is in 46 days.
How were Tsumura & Co.’s earnings last quarter?
Tsumura & Co. released its earnings results on Feb 06, 2026. The company reported ¥142.95 earnings per share for the quarter, beating the consensus estimate of ¥90.935 by ¥52.015.
Is Tsumura & Co. overvalued?
According to Wall Street analysts Tsumura & Co.’s price is currently Overvalued.
Does Tsumura & Co. pay dividends?
Tsumura & Co. pays a Semiannually dividend of ¥76 which represents an annual dividend yield of 3.3%. See more information on Tsumura & Co. dividends here
What is Tsumura & Co.’s EPS estimate?
Tsumura & Co.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tsumura & Co. have?
Tsumura & Co. has 76,758,360 shares outstanding.
What happened to Tsumura & Co.’s price movement after its last earnings report?
Tsumura & Co. reported an EPS of ¥142.95 in its last earnings report, beating expectations of ¥90.935. Following the earnings report the stock price went up 1.353%.
Which hedge fund is a major shareholder of Tsumura & Co.?
Currently, no hedge funds are holding shares in JP:4540
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Tsumura & Co.
Tsumura & Co. (4540) is a leading Japanese pharmaceutical company specializing in traditional herbal medicine, also known as Kampo medicine. Established in 1893, the company develops, manufactures, and sells a wide range of Kampo products, which are derived from natural herbal ingredients. Tsumura operates primarily in the healthcare sector, focusing on providing effective and safe therapeutic solutions that align with Japan's rich history of herbal medicine. In addition to Kampo formulations, the company is involved in research and development of new pharmaceuticals and operates in the field of health foods.
Technical Analysis
Hisamitsu Pharmaceutical Co
―
Kaken Pharmaceutical Co
―
Mochida Pharmaceutical Co., Ltd.
―
Pharma Foods International Co., Ltd.
―
Nippon Shinyaku Co., Ltd.
―
Options Prices
Currently, No data available
---